Search Results for “Takeda” – Page 9 – media

Re-Investigation on FDA Approved Anti-Gout Drug Uloric

When the FDA approved this drug, there was an additional demand from the FDA to conduct post-marketing studies and assess the drug’s safety. Recently, a non-profit consumer advocacy group sent a petition requesting that the FDA should eliminate the drug from the U.S. pharma market since the drug shows significant risk of cardiovascular diseases.
- Source: FiercePharma
- 685
- June 25, 2018
cardiovascular disease Clinical Trials gout Takeda
Crescendo and China’s Zai Labs Enters into Psoriasis Drug Deal

This is the second partnership of the firm, the first outside oncology. It has a USD 790 million collaboration signed in 2016 with drugmaker Takeda of Japan. The deal with Zai Lab is the first for Crescendo to involve a specific pipeline asset. The deal with Takeda was more of a platform agreement giving it the required confidence to collaborate with other programs in oncology.
- Source: Ddu
- 761
- June 1, 2018
Clinical Trials Company Insights psoriasis
Johnson & Johnson’s Darzalex snags landmark myeloma approval in first-line patients

EHR vendor Allscripts has made an agreement to purchase patient communication app maker Health Grid for $60 million in cash, with an additional $50 million in earnout payments based on Health Grid achieving certain revenue targets over the next three years, according to a recently registered SEC filing. The merger of the two companies is expected to close sometime during Q2 2018.
- Source: fiercepharma
- 577
- May 10, 2018
Darzalex Johnson & Johnson myeloma
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Sale of Oncology business unlocks embedded value within Shire`s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases
- Source: finance.yahoo
- 657
- April 17, 2018
Company Insights oncology rare diseases
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors;

Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhibitor of RIPK1 in a Phase 1 clinical trial in healthy volunteers and achieved proof of concept of its large molecule blood-brain barrier delivery platform technology in nonhuman primates.
- Source: Nasdaq
- 560
- March 21, 2018
Clinical Trial neurodegenerative disease RIPK1
Finch Therapeutics Raises $36 Million Series B, Bringing Total to $77 Million

Finch Therapeutics, headquartered in Somerville, Massachusetts, closed on an oversubscribed Series B financing worth $36 million. Since the company’s launch, it has raised $77 million. Series B investors included Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital.
- Source: Biospace
- 567
- March 6, 2018
Market Views microbiome Series
Japanese pharma set for transformation in 2018

This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
- Source: PharmaPhorum
- 950
- February 2, 2018
biosimilars CPhI Market Views pharmaceutical
NICE becomes latest champion for digital health

NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
- Source: Pharma Phorum
- 747
- February 1, 2018
Company Insight digital health EHR NICE
AstraZeneca’s Three-in-One COPD Inhaler Succeeds in Phase III Trial

AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights. This morning, AstraZeneca revealed Phase III data that shows its experimental three-in-one inhaler PT010 improved lung function in patients.
- Source: Biospace
- 587
- January 29, 2018
Clinical Trials COPD inhaler
Mallinckrodt inks $1.2B Sucampo buy, ending rough 2017 on a high note

Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller.
- Source: fiercepharma
- 440
- December 28, 2017
chronic Company Insight constipation Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.